Edition:
United Kingdom

Pharmaceuticals

Page 1

Jubilant Life Sciences Says Approved Demerger Of The Life Science Ingredients Business

Friday, 25 Oct 2019

Oct 25 (Reuters) - Jubilant Life Sciences Ltd ::JUBILANT LIFE SCIENCES LTD SAYS HAS APPROVED DEMERGER OF THE LIFE SCIENCE INGREDIENTS BUSINESS.

North Bud Farms Signs Offer To Buy 11-Acre Property In Salinas, California

Thursday, 12 Sep 2019

Sept 12 (Reuters) - North Bud Farms Inc ::NORTH BUD FARMS RESTRUCTURES PROPOSED CALIFORNIA OPERATIONS WITH SIGNING OF OFFER TO PURCHASE 11-ACRE PROPERTY IN SALINAS, CALIFORNIA.NORTH BUD FARMS INC - TRANSACTION IS VALUED AT USD$11 MILLION..

Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth And Focus On Innovative Research And Development

Thursday, 20 Jun 2019

June 20 (Reuters) - Merck & Co Inc ::MERCK HOSTS 2019 INVESTOR DAY OUTLINING BUSINESS MOMENTUM, STRONG EXPECTED GROWTH AND FOCUS ON INNOVATIVE RESEARCH AND DEVELOPMENT.MERCK & CO INC - "MOMENTUM ACROSS KEY PILLARS EXPECTED TO DRIVE STRONG REVENUE GROWTH EVERY YEAR OVER NEXT FIVE YEARS, INCLUDING 2023".MERCK & CO INC - MEANINGFUL OPERATING MARGIN EXPANSION EXPECTED.MERCK & CO INC - "MERCK WILL CONTINUE TO EVOLVE ITS OPERATING MODEL TO BUILD A LEANER, MORE EFFICIENT ORGANIZATION.".

Navamedic: NAVA And OM ASA Sign Joint Demerger Plan

Wednesday, 19 Jun 2019

June 19 (Reuters) - Navamedic ASA ::PROPOSED DEMERGER OF NAVAMEDIC ASA WITH TRANSFER TO OBSERVE MEDICAL ASA.BOARD OF DIRECTORS OF NAVA AND OM ASA TODAY ANNOUNCE THAT THEY HAVE SIGNED A JOINT DEMERGER PLAN.UPON COMPLETION OF DEMERGER, OBSERVE MEDICAL INTERNATIONAL AB WILL BE A WHOLLY OWNED SUBSIDIARY OF OM ASA AND OM ASA WILL INDIRECTLY BE OWNER OF OBSERVE MEDICAL INTERNATIONAL AB'S DIRECT AND INDIRECT SUBSIDIARIES.BOARDS OF NAVA AND OM ASA HAVE RESOLVED UPON AN EXCHANGE RATIO OF 74%/26%, WITH 74% OF BUSINESS TO REMAIN IN NAVA AND 26% OF BUSINESS BEING TRANSFERRED TO OM ASA.BOARD OF DIRECTORS OF NAVA AND OM ASA RESOLVED TO PROPOSE TO THEIR RESPECTIVE GENERAL MEETINGS THAT SHAREHOLDERS SHALL APPROVE DEMERGER OF NAVA.CURRENT BOARD OF DIRECTORS AND MANAGEMENT OF NAVA WILL NOT BE AFFECTED BY DEMERGER.DEMERGER WILL NOT HAVE ANY IMPLICATIONS FOR EMPLOYEES OF NAVA GROUP.

Co.Don AG: Strategic Expansion And Further Internationalisation

Wednesday, 13 Mar 2019

March 13 (Reuters) - CO.DON AG ::DGAP-NEWS: CO.DON AG: STRATEGIC EXPANSION AND FURTHER INTERNATIONALISATION.IS REVIEWING VARIOUS FINANCING OPTIONS, WHICH INCLUDE POSSIBILITY OF RAISING EQUITY.

Sellas Life Sciences Announces Review Of Strategic Alternatives

Tuesday, 26 Feb 2019

Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES.SELLAS LIFE SCIENCES ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES.SELLAS LIFE SCIENCES GROUP INC - DISCUSSIONS ON DEVELOPMENT PATH FOR NELIPEPIMUT-S (NPS) ONGOING WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA).SELLAS LIFE SCIENCES GROUP INC - DISCUSSIONS ON DEVELOPMENT PATH FOR NELIPEPIMUT-S (NPS) ONGOING WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA).SELLAS LIFE SCIENCES GROUP INC - ENGAGES CANTOR FITZGERALD & CO. IN ITS REVIEW OF STRATEGIC ALTERNATIVES AS IT SEEKS TO MAXIMIZE SHAREHOLDER VALUE.SELLAS LIFE SCIENCES GROUP INC - PLANS TO EXPLORE A WIDE RANGE OF STRATEGIC ALTERNATIVES THAT INCLUDE, AMONG OTHERS, A SALE OF COMPANY,OTHERS.SELLAS LIFE SCIENCES - DOES NOT EXPECT TO DISCUSS/DISCLOSE DEVELOPMENTS REGARDING STRATEGIC PROCESS UNLESS AND UNTIL ITS BOARD HAS APPROVED ACTION.SELLAS LIFE SCIENCES - STRATEGIC ALTERNATIVES ALSO INCLUDE MERGER/ REVERSE MERGER WITH ANOTHER COMPANY, STRATEGIC INVESTMENT/FINANCING,OTHERS.SELLAS LIFE SCIENCES- PLANNED PHASE 3 PROSPECTIVE STUDY OF GPS MONOTHERAPY IN PATIENTS WITH AML WHO ACHIEVED MORPHOLOGICAL SECOND COMPLETE RESPONSE.SELLAS -ALTERNATIVES ALSO HAS FUNDED COLLABORATION/PARTNERSHIP WOULD ALLOW TO CONTINUE CURRENT BUSINESS PLAN OF ADVANCING DEVELOPMENT OF GPS, NPS.

Vistin Pharma To Close Energy Trading Business Unit Acitvity

Tuesday, 8 Jan 2019

Jan 8 (Reuters) - Vistin Pharma ASA ::REG-VISTIN PHARMA ASA : UPDATE ON ENERGY TRADING BUSINESS.SAYS WILL CONTINUE TO MANAGE OUTSTANDING FINANCIAL DERIVATIVE CONTRACTS, BUT WILL NOT ENTER INTO NEW ENERGY TRADING INVESTMENTS AND CLOSE ENERGY TRADING BUSINESS.TO CLOSE ENERGY TRADING BUSINESS UNIT ACITVITY.CURRENT MARKET CONDITIONS HAVE MADE IT DIFFICULT TO RAISE EXTERNAL CAPITAL FOR CLOSED-END FUNDS.TRADING POSITIONS TAKEN BY COMPANY HAS SO FAR NOT PERFORMED AS PLANNED.WILL NOT ENTER INTO NEW ENERGY TRADING INVESTMENTS AND CLOSE ENERGY TRADING BUSINESS.NO NEW ENERGY TRADING INVESTMENTS WILL BE MADE.

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary